Ae. Hunter et al., BONE-MARROW TRANSPLANTATION - CURRENT SITUATION, COMPLICATIONS AND PREVENTION, Journal of antimicrobial chemotherapy, 36, 1995, pp. 119-133
The number of patients undergoing BMT is rising steadily. The increase
is due to a broadening of the indications for transplantation and an
increase in the donor pool. There has been a progressive improvement i
n outcome particularly due to a fall in transplant-related mortality.
Methotrexate and cyclosporin are the mainstay of graft versus host dis
ease (GVHD) prophylaxis, but acute GVHD remains a major problem in the
unrelated donor recipient. Infections remain an important cause of de
ath and emphasise the crucial role of antimicrobial prophylaxis; death
from Gram-negative sepsis has been significantly reduced by the use o
f prophylactic antibiotics. Fungal infections carry a high mortality,
especially in allogeneic transplant recipients. Fluconazole is used to
protect patients in the neutropenic period and beyond in higher risk
individuals. Viral infections, which may occur late, are emerging as a
significant cause of morbidity and mortality in the allogeneic, parti
cularly unrelated transplantation setting. A long term susceptibility
to encapsulated bacteria suggests delayed immune reconstitution; revac
cination policies are standard in most units. The longer term effects
of transplantation are increasingly important with improving survival
and include chronic GVHD, endocrine, cardiorespiratory and other syste
mic abnormalities. The increased risk of secondary malignancies is als
o of concern.